SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

• Sagimet plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026 following positive late-stage results in China, which showed a favorable safety profile.
• The biotech firm priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, a 2.4% premium over its closing price on Friday.
• Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028.

Shares of Sagimet Biosciences (SGMT) jumped more than 40% on Monday, breaking the 200-day moving average for the first time since early February, after the company priced its latest share offering at a premium and reported positive progress on its acne drug.

SGMT shares recorded their biggest intraday gains in more than 27 months, rising to their highest levels in over 5 months.

Source: TradingView

$175M Offering To Boost Acne Treatment Pipeline

Sagimet priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, aiming to raise roughly $175 million in gross proceeds. This represented a 2.4% premium to the stock’s closing price on Friday. The offering is expected to close around April 28, 2026.

The clinical-stage biotech firm plans to use the funds to advance its pipeline, including a Phase 3 trial of its lead drug candidate Denifanstat for acne. Proceeds will also support the development of TVB-3567, a small-molecule inhibitor of fatty acid synthase (FASN) for acne treatment.

Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028, including key trial readouts. The remaining funds will be used for general corporate purposes, including clinical development, working capital, and operating expenses.

Denisfanstat Acne Treatment In Focus

Sagimet is advancing its acne treatment pipeline, with plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026. The move follows positive late-stage results in China, where the once-daily oral therapy showed good safety and sustained improvement in patients with moderate to severe acne.

The company is also progressing its broader pipeline. Sagiment announced plans to move its TVB-3567, currently in a Phase 1 trial, into Phase 2 studies later this year. Meanwhile, development in metabolic dysfunction-associated steatohepatitis (MASH) is expected to be paused until the company secures non-dilutive funding.

How Did Retail Traders React?

Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform remained ‘extremely high.’

One user said the company’s acne treatment “has blockbuster potential.”

Another user said SGMT is “now a $50-100 value stock” given the “resoundingly positive phase 3” trial.

The stock has gained around 40% so far this year.

Read also: TSLA Stock In Spotlight As EV Maker Registers Shares Tied To Elon Musk’s 2018 Pay Package – Retail Sees Imminent Sell-Off

For updates and corrections, email newsroom[at]stocktwits[dot]com.